Clinical Trials: Clinical Trials in China

Site Selection Strategy in China’s Expanding Research Network

October 16, 2025

Sponsors should:
– Balance site selection between Tier-1 and Tier-2 hospitals.
– Conduct robust feasibility and patient pool assessments.
– Verify site accreditation and ethics committee capacity.
– Provide additional training and monitoring for less experienced sites.
– Partner with CROs for site evaluation and operational support.
– Audit site compliance during initiation to ensure readiness.
These best practices reduce risks and enhance trial efficiency.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Patient Informed Consent Challenges in Rural China

October 16, 2025

digi

Sponsors should:
– Develop simplified consent forms with plain language and visuals.
– Translate documents into local dialects where needed.
– Implement eConsent tools with video and interactive features.
– Provide investigator training in communication and cultural sensitivity.
– Involve patient advocacy groups to review consent materials.
– Monitor rural sites closely for consent compliance.
These practices strengthen informed consent processes and protect patient rights.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

How Traditional Medicine Trials Are Evaluated by NMPA

October 16, 2025

digi

Sponsors should:
– Standardize herbal raw material sourcing and quality testing.
– Design hybrid endpoints combining TCM and biomedical measures.
– Train investigators in both TCM diagnostics and GCP standards.
– Engage ethics committees early to validate culturally relevant trial designs.
– Document historical use alongside clinical trial data.
– Implement rigorous pharmacovigilance systems for multi-herbal formulations.
These strategies improve trial credibility and regulatory acceptance.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Bioequivalence Trials for Generics in China: Case Examples

October 17, 2025

digi

Sponsors should:
– Partner with NMPA-accredited sites and GLP-certified laboratories.
– Standardize sample collection and handling procedures.
– Validate all PK assays before trial initiation.
– Conduct mock inspections to test data integrity.
– Train site staff in protocol compliance and EDC systems.
– Ensure diet and fasting conditions are strictly monitored during dosing.
These practices minimize risks of inspection findings and trial delays.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Outsourcing Trends: Global CROs vs Local CROs in China

October 17, 2025

digi

Sponsors should:
– Conduct rigorous due diligence on CROs’ regulatory compliance history.
– Balance trial needs with CRO strengths—global for multinational oversight, local for operational execution.
– Implement strong oversight mechanisms and QA audits for CRO partners.
– Use hybrid outsourcing models where appropriate to maximize efficiency.
– Ensure CRO staff are trained in ICH E6(R2) and NMPA-specific requirements.
– Establish clear contractual obligations for data integrity and inspection readiness.
These practices enhance collaboration and reduce outsourcing risks.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Clinical Trial Metrics Benchmarking: China vs US vs EU

October 17, 2025

digi

Sponsors should:
– Benchmark timelines and costs against regional averages during planning.
– Use Tier-1 hospitals in China for faster activation and higher data quality.
– Incorporate training programs for Tier-2 sites to expand recruitment.
– Align trial designs with ICH E17 MRCT guidance for multinational data acceptance.
– Implement bilingual systems to ensure accurate data integration across regions.
– Conduct mock inspections to prepare Chinese sites for FDA, EMA, and NMPA reviews.
These practices improve efficiency and harmonization across regions.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials

Ethical Challenges in Pediatric Oncology Trials in China

October 18, 2025

digi

Sponsors should:
– Use age-appropriate, illustrated consent and assent materials.
– Involve both parents and children in decision-making while respecting cultural norms.
– Establish specialized pediatric trial sites with trained staff.
– Strengthen ethics committee oversight for pediatric oncology protocols.
– Engage patient advocacy groups for recruitment support.
– Implement pediatric-specific safety monitoring systems.
These measures ensure ethical compliance and patient protection.

Click to read the full article.

Clinical Trials in China, Country-Specific Clinical Trials